CJC-1295 No DAC + Ipamorelin Stack: Researcher's Guide to Mechanisms, Synergy & Preclinical Findings (2026)

The CJC-1295 No DAC and Ipamorelin stack represents one of the most extensively studied peptide combinations in preclinical growth hormone (GH) secretagogue research. These two synthetic peptides operate through distinct but complementary receptor pathways — CJC-1295 No DAC as a growth hormone-releasing hormone (GHRH) analogue, and Ipamorelin as a selective ghrelin receptor agonist — generating substantial interest among researchers investigating pulsatile GH axis biology. Understanding the mechanistic interplay between these two compounds is central to interpreting the preclinical literature surrounding GH secretagogue combinations.

In laboratory settings, scientists have explored how co-administration of GHRH analogues and ghrelin mimetics may produce additive or synergistic effects on GH pulse amplitude and downstream signaling cascades. The CJC-1295 No DAC / Ipamorelin pairing has become a standard reference model for studying dual-pathway GH axis modulation in rodent and cell-culture systems.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. All compounds described are for in-vitro and preclinical research use only and are not intended for human or animal administration.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Ipamorelin — 10MG

Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$55.00 ($41.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is CJC-1295 No DAC?

CJC-1295 No DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 29-amino-acid truncated peptide designed to bind to GHRH receptors on pituitary somatotrophs. Unlike its DAC-conjugated counterpart, the No DAC form lacks the Drug Affinity Complex, resulting in a shorter active half-life that researchers have used to study discrete, pulsatile GH secretion patterns in preclinical models.

What is Ipamorelin and how does it differ from other GH secretagogues?

Ipamorelin is a pentapeptide ghrelin receptor (GHSR-1a) agonist. Preclinical studies have distinguished it from earlier GH secretagogues by its selectivity profile — research in animal models has suggested that Ipamorelin stimulates GH release with minimal concurrent stimulation of cortisol or prolactin pathways, making it a useful reference tool for isolated GH axis studies.

Why do researchers study CJC-1295 No DAC and Ipamorelin together?

The two peptides engage separate receptor systems — GHRH receptors (via CJC-1295 No DAC) and GHSR-1a receptors (via Ipamorelin) — that converge on pituitary somatotrophs. Preclinical models have investigated whether this dual-pathway stimulation produces a greater GH pulse amplitude than either compound in isolation, exploring potential synergistic mechanisms at the cellular signaling level.

What receptor pathways are involved in this peptide stack?

CJC-1295 No DAC activates the GHRH receptor (GHRHR), primarily signaling through adenylyl cyclase and cyclic AMP (cAMP) pathways. Ipamorelin acts on the growth hormone secretagogue receptor 1a (GHSR-1a), which couples to phospholipase C and intracellular calcium mobilization. Research suggests these parallel intracellular cascades may reinforce each other at the level of GH exocytosis from pituitary somatotroph cells.

How does CJC-1295 No DAC differ from CJC-1295 with DAC?

The DAC (Drug Affinity Complex) modification attaches the peptide to circulating albumin, dramatically extending its half-life and producing a sustained, non-pulsatile GH elevation in preclinical models. CJC-1295 No DAC lacks this modification, producing shorter-duration receptor activation that researchers use to model the natural episodic pattern of GHRH signaling, more closely mimicking endogenous GH pulse architecture.

What has preclinical research found about GH pulse amplitude with this combination?

In vitro and rodent studies have examined pituitary GH release following dual GHRH analogue and GHSR agonist stimulation. Findings from several preclinical models have indicated that simultaneous engagement of both receptor pathways can produce GH release responses greater than those observed with either peptide alone, a phenomenon researchers have characterized as synergistic somatotroph stimulation.

Is this peptide stack available for laboratory research?

Yes. CJC-1295 No DAC and Ipamorelin are available as reference materials for in-vitro and preclinical laboratory research. They are supplied as lyophilized peptides for reconstitution in research settings. These materials are not for human or animal use.

What downstream signaling events have been studied in this context?

Preclinical research has examined downstream signaling including IGF-1 axis activation, STAT5b phosphorylation, and transcriptional regulation of growth-related genes following GH axis stimulation. Studies have also explored how pulsatile versus continuous GH exposure patterns differentially regulate hepatic and peripheral IGF-1 production in rodent models.

GHRH and Ghrelin Biology: The Dual Axis of GH Secretion

To understand why the CJC-1295 No DAC and Ipamorelin combination attracts scientific attention, researchers must first appreciate the dual neuroendocrine control of GH secretion. The hypothalamic-pituitary GH axis is governed primarily by two opposing peptide signals: growth hormone-releasing hormone (GHRH), which stimulates GH secretion, and somatostatin, which inhibits it. Overlaid on this system is the ghrelin pathway — an independent stimulatory input that acts through the GHSR-1a receptor and can potentiate GHRH-driven GH release.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Ipamorelin — 10MG

$55.00 ($41.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

As explored in the CJC-1295 peptide research guide, GHRH receptor signaling is mediated primarily through Gs protein coupling, adenylyl cyclase activation, and intracellular cAMP accumulation. This cascade ultimately triggers voltage-gated calcium channel opening and GH-containing secretory granule exocytosis from somatotroph cells. The natural GHRH peptide has a short plasma half-life due to rapid dipeptidyl peptidase IV (DPP-IV) cleavage, and synthetic analogues like CJC-1295 No DAC were designed in part to study sustained receptor engagement in the absence of rapid degradation.

Ghrelin Receptor Biology and GHSR-1a Signaling

The ghrelin receptor (GHSR-1a) pathway, through which Ipamorelin operates, engages a distinct intracellular cascade. As covered in depth in the Ipamorelin mechanisms and research applications guide, GHSR-1a is a G-protein coupled receptor that signals through Gq/11 proteins, activating phospholipase C-beta, generating inositol triphosphate (IP3), and triggering calcium release from intracellular stores. This distinct calcium mobilization mechanism converges with the GHRH-driven calcium influx at the level of secretory granule fusion with the plasma membrane.

Preclinical electrophysiology and calcium imaging studies have demonstrated that simultaneous GHRH and ghrelin receptor co-stimulation produces calcium transients in somatotroph cells that are quantitatively greater than those produced by either ligand alone — a cellular correlate of the enhanced GH release that has been documented in rodent in vivo models.

CJC-1295 No DAC: Mechanistic Profile in Preclinical Research

CJC-1295 No DAC is a 29-amino-acid peptide that shares substantial sequence homology with native GHRH(1-29), the biologically active fragment of the full 44-amino-acid GHRH molecule. Key amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to DPP-IV cleavage and other proteolytic enzymes that rapidly degrade native GHRH in plasma. These modifications extend the functional receptor-binding window without the albumin-binding DAC modification, preserving a half-life that researchers have estimated at approximately 30 minutes in rodent models — compared to the minutes-long window of native GHRH.

Pulsatility and No DAC Research Rationale

A central theme in GHRH analogue research is the physiological importance of pulsatile GH secretion. Natural GH release occurs in discrete pulses, and preclinical evidence suggests that continuous, non-pulsatile GH exposure may produce different receptor regulation and downstream signaling outcomes compared to pulsatile patterns. The shorter half-life of CJC-1295 No DAC makes it a preferred research tool for scientists who specifically wish to model episodic somatotroph stimulation, as opposed to the prolonged, flattened GH curves produced by DAC-modified analogues.

Rodent studies have used CJC-1295 No DAC to investigate how GHRH receptor desensitization and resensitization cycles influence cumulative GH output over 24-hour and multi-day observation windows. Receptor internalization and recycling kinetics have been characterized as important variables in these experimental designs.

CJC 1295 No DAC (10MG) + Ipamorelin (10MG) – 20MG for research →

Ipamorelin: Selectivity Profile and Preclinical Research Applications

Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide that was developed as a highly selective GHSR-1a agonist. Early preclinical pharmacology studies compared its receptor selectivity to that of first-generation GH secretagogues such as GHRP-2 and GHRP-6. A landmark preclinical study published in the late 1990s characterized Ipamorelin’s selectivity profile in rat pituitary cells and in vivo models, demonstrating that it stimulated robust GH release while producing substantially smaller concurrent elevations in ACTH and cortisol compared to earlier secretagogues — a selectivity profile that has made it a preferred tool for isolating GH axis-specific experimental effects.

GHSR-1a Agonism Mechanisms

At the molecular level, Ipamorelin stabilizes an active conformation of GHSR-1a that promotes Gq/11 coupling with high efficiency. Research in heterologous expression systems has examined the structural basis for Ipamorelin’s receptor interactions, mapping key contact residues within the GHSR-1a binding pocket that distinguish it from endogenous ghrelin. These structural studies have informed the broader understanding of how peptide secretagogues can be engineered for receptor subtype selectivity.

Somatostatin’s inhibitory tone is a critical variable in ghrelin research. Preclinical studies have explored whether GHSR-1a agonism by compounds like Ipamorelin can partially overcome somatostatin-mediated GH suppression, with some rodent data suggesting that ghrelin receptor activation may modulate somatostatin neuron activity at the hypothalamic level — a potential additional mechanism beyond direct pituitary stimulation.

Ipamorelin – 10MG Nasal Spray for research →

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

Synergistic Mechanisms: Dual-Pathway GH Axis Stimulation

The scientific rationale for co-investigating CJC-1295 No DAC and Ipamorelin lies in the convergence of their respective signaling cascades at multiple levels of the GH secretion apparatus. Preclinical models have examined at least three potential loci of synergy: intracellular second messenger convergence, somatostatin axis modulation, and hypothalamic-pituitary feedback loop dynamics.

Second Messenger Convergence

cAMP-dependent protein kinase A (PKA) signaling from GHRHR activation and IP3/calcium signaling from GHSR-1a activation have been shown in cell-based systems to converge on shared downstream effectors, including the transcription factor CREB and the secretory machinery proteins governing granule exocytosis. Studies using pituitary cell lines have demonstrated that simultaneous cAMP and calcium elevation produces synergistic rather than simply additive GH secretion responses, an outcome attributed to the cooperative interaction of these parallel kinase cascades at the secretory machinery level.

Somatostatin Counteraction Research

A particularly active area of investigation concerns the ability of GHSR-1a agonists to reduce hypothalamic somatostatin release, thereby reducing inhibitory tone on pituitary somatotrophs and amplifying the stimulatory effect of concomitant GHRH receptor activation. Rodent hypothalamic slice preparation studies have examined ghrelin’s inhibitory effects on periventricular nucleus somatostatin neurons, with findings suggesting that this central disinhibitory mechanism may substantially augment the total GH output achieved when GHRH receptor agonism is applied simultaneously.

Pulse Architecture Studies

Researchers have used frequent-sampling GH radioimmunoassay protocols in rodent models to characterize how the CJC-1295 No DAC / Ipamorelin combination influences GH pulse amplitude, pulse frequency, interpulse nadir concentrations, and mean 24-hour GH exposure. Studies have generally reported that pulse amplitude — rather than pulse frequency — is the primary variable enhanced by dual-peptide administration, consistent with the convergent somatotroph stimulation hypothesis.

CJC 1295 No DAC (5MG) + Ipamorelin (5MG) – 10MG Nasal Spray for research →

Downstream Biology: IGF-1 Axis and Tissue-Level Research

GH exerts many of its tissue-level effects indirectly through stimulation of hepatic IGF-1 production. Preclinical studies have therefore examined how GHRH analogue / ghrelin receptor agonist combinations influence downstream IGF-1 axis signaling, including circulating IGF-1 concentrations, IGF-1 receptor phosphorylation, and STAT5b-mediated transcriptional responses in liver tissue. The MOTS-C preclinical research guide provides useful comparative context for how metabolic peptides modulate overlapping cellular signaling networks.

Researchers studying the CJC-1295 No DAC / Ipamorelin combination in rodent models have quantified hepatic IGF-1 mRNA expression, circulating IGF-1 protein levels, and phosphorylation of downstream signaling intermediates including AKT and ERK1/2 in muscle and adipose tissue preparations. These tissue-level endpoints provide mechanistic confirmation of GH axis activation beyond pituitary GH release alone.

Bone and Connective Tissue Research Context

Preclinical investigations have also examined GH axis peptide combinations in the context of connective tissue biology. Several studies using rodent bone organ culture models have explored whether GHRH analogue and ghrelin receptor agonist co-stimulation influences osteoblast activity markers, collagen synthesis rates, and bone mineral apposition parameters — endpoints of interest when studying how the GH/IGF-1 axis interfaces with skeletal biology. These findings are frequently interpreted alongside data from related tissue repair peptides such as those examined in the TB-500 tissue biology research guide.

Research Design Considerations for CJC-1295 No DAC / Ipamorelin Studies

Scientists designing preclinical experiments with this peptide combination should consider several key variables that have emerged from the published literature. Timing of peptide administration relative to the endogenous GH secretory rhythm is a critical experimental parameter — rodent GH pulsatility follows an approximately 3.3-hour ultradian cycle, and the GH response to exogenous secretagogues varies substantially depending on whether administration occurs at a GH pulse peak versus nadir. Most published protocols have administered peptides during established GH interpulse nadirs to maximize measurable response amplitude.

Peptide reconstitution quality is another variable that can significantly influence experimental reproducibility. The bacteriostatic water quality guide outlines the importance of sterile reconstitution media in maintaining peptide stability and experimental consistency across multi-day study protocols.

Additionally, sex differences in GH pulse architecture are well-documented in rodent models — female rats typically exhibit higher pulse frequency but lower peak amplitude compared to males — and researchers should stratify or control for sex as a biological variable in experimental designs involving GH secretagogue combinations.

Pfizer Hospira Bacteriostatic Water – 30 mL for research →

Where These Fit in Your Research Library

The CJC-1295 No DAC / Ipamorelin combination anchors GH axis research programs. Researchers may also find the following materials relevant:

CJC1295 w/ DAC – 5MG Nasal Spray — for comparison studies of pulsatile versus sustained GHRH receptor engagement
IGF-1 LR3 1MG — for downstream IGF-1 axis studies alongside GH secretagogue research
CJC 1295 No DAC + Ipamorelin – 20MG combination — the complete research stack

Final Takeaway: CJC-1295 No DAC + Ipamorelin as a Dual-Pathway Research Model

The CJC-1295 No DAC and Ipamorelin combination has established itself as a foundational model in preclinical GH axis research precisely because it exploits two mechanistically distinct receptor systems — GHRHR cAMP signaling and GHSR-1a calcium mobilization — whose downstream convergence on pituitary somatotrophs provides a tractable system for studying synergistic secretagogue biology. Preclinical studies have consistently demonstrated enhanced GH pulse amplitude with dual-peptide administration relative to single-agent controls, alongside downstream IGF-1 axis activation and tissue-level signaling responses that make this combination valuable for scientists across endocrinology, metabolic biology, and connective tissue research.

For laboratory researchers building a comprehensive GH biology research program, CJC-1295 No DAC and Ipamorelin represent well-characterized, mechanistically rationalized tools with a substantial published preclinical foundation. All materials should be handled according to institutional laboratory guidelines for peptide research compounds.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

CJC-1295 No DAC + Ipamorelin Stack: Researcher’s Guide to Mechanisms, Synergy & Preclinical Findings (2026)